Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000 Jan 18;97(2):779-82.
doi: 10.1073/pnas.97.2.779.

Benzo[a]pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor

Affiliations

Benzo[a]pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor

Y Shimizu et al. Proc Natl Acad Sci U S A. .

Abstract

The contribution of the aryl hydrocarbon receptor (AhR) in induction of a battery of xenobiotic-metabolizing enzymes has been studied extensively. However, no direct proof has been obtained that it plays a role in modulating carcinogenesis. To address the question of whether AhR is required for tumor induction, we have investigated the response of AhR-deficient mice to benzo[a]pyrene (B[a]P), a widely distributed environmental carcinogen. B[a]P treatment induced expression of the cytochrome P450 gene Cyp1a1 in the skin and liver of AhR-positive mice bearing +/+ and +/- genotypes and did not induce expression of the cytochrome P450 gene Cyp1a1 in AhR-null mice in either skin or liver. In contrast, Cyp1a2 gene expression was positive in liver irrespective of the presence or absence of the AhR gene, or B[a]P treatment, although its inducibility was lost in the AhR(-/-) mouse. All AhR-positive male mice of both +/+ and +/- genotypes that received subcutaneous injection of B[a]P (2 mg) on the first and the eighth days had developed subcutaneous tumors at the site of injection at the end of the 18-week experiment. In contrast, no tumors were apparent in any of the AhR-deficient mice. Likewise, topical application of B[a]P (200 microg) at weekly intervals to the skin of female mice for 25 weeks produced skin tumors only in the AhR-positive mice. Thus the carcinogenic action of B[a]P may be determined primarily by AhR, a transcriptional regulator of the gene for CYP1A1. The results of the present study provide direct evidence that AhR is involved in carcinogenesis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cyp1a1, Cyp1a2, and AhR gene expression in the skin and liver of AhR(+/+), AhR(+/−), and AhR(−/−) mice, with and without B[a]P treatment. One-microgram aliquots of RNA extracted from skin and liver of control and B[a]P-treated mice of the three genotypes were reverse-transcribed and analyzed by PCR using specific primers for the Cyp1a1, Cyp1a2, and AhR and β-actin genes.
Figure 2
Figure 2
Subcutaneous tumor induction in wild-type (▵) and AhR-deficient male mice (+/−, □; −/−, ○) injected with B[a]P.
Figure 3
Figure 3
Gross appearance of flank skins in AhR-wild-type mice (+/+), AhR-heterozygous mice (+/−), and AhR-deficient mice (−/−) injected subcutaneously with B[a]P.
Figure 4
Figure 4
(A–C) Histological appearance of a fibrosarcoma (A), a rhabdomyosarcoma (B), and a squamous cell carcinoma (C) induced in AhR(+/+) male mice by subcutaneous injection of B[a]P. (Hematoxylin/eosin staining, ×100.) (D–F) Histological appearance of a squamous cell carcinoma (D), papilloma (E), and keratoacanthoma (F) induced in AhR(+/+) female mice by topical application of B[a]P. (Hematoxylin/eosin staining, ×100 for D, ×5 for E and F.)
Figure 5
Figure 5
Skin tumor induction in AhR-wild-type (+/+) (▵) and AhR-deficient female mice (+/−, □; −/−, ○) by repeated topical application of B[a]P.
Figure 6
Figure 6
Gross appearance of skin tumors in AhR-deficient (−/−), AhR-heterozygous (+/−), and AhR-wild-type (+/+) female mice after repeated topical application of B[a]P.

References

    1. Jones P B C, Galeazzi D R, Fisher J M, Whitlock J P., Jr Science. 1985;227:1499–1502. - PubMed
    1. Gonzalez F J, Tukey R H, Nebert D W. Mol Pharmacol. 1984;26:117–121. - PubMed
    1. Sutter T R, Tang Y M, Hayes C L, Wo Y-Y P, Jabs E W, Li X, Yin H, Cody C W, Greenlee W F. J Biol Chem. 1994;269:13092–13099. - PubMed
    1. Telakowski-Hopkins C A, Hing R G, Pickett C B. Proc Natl Acad Sci USA. 1988;85:1000–1004. - PMC - PubMed
    1. Favreau L V, Pickett C B. J Biol Chem. 1991;266:4556–4561. - PubMed

Publication types

MeSH terms